Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractionated dosing of [211At]MABG in Relapsed/Refractory Neuroblastoma
NCT07767630Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of astatobenguane [211At] in neuroblastoma, sponsored by Sichuan University. Primary endpoints: Dose-limiting toxicities at 4 weeks and Adverse Events at 4 weeks. Started Jul 2026; status: recruiting.
02
Drugs
astatobenguane [211At]
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT07767630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767630.